Bone Degeneration and Recovery after Early and Late Bisphosphonate Treatment of Ovariectomized Wistar Rats Assessed by In Vivo Micro-Computed Tomography

Bisphosphonates are antiresorptive drugs commonly used to treat osteoporosis. It is not clear, however, what the influence of the time point of treatment is. Recently developed in vivo micro-computed tomographic (CT) scanners offer the possibility to study such effects on bone microstructure in rats. The aim of this study was to determine the influence of early and late zoledronic acid treatment on bone in ovariectomized rats, using in vivo micro-CT. Twenty-nine female Wistar rats were divided into the following groups: ovariectomy (OVX, n = 5), OVX and zoledronic acid (ZOL) at week 0 (n = 8), OVX and ZOL at week 8 (n = 7), and sham (n = 9). CT scans were made of the proximal tibia at weeks 0, 2, 4, 8, 12, and 16; and bone structural parameters were determined in the metaphysis. Two fluorescent labels were administered to calculate dynamic histomorphometric parameters. At week 16, all groups were significantly different from each other in bone volume fraction (BV/TV), connectivity density, and trabecular number (Tb.N), except for the early ZOL and control groups which were not significantly different for any structural parameter. After ZOL treatment at week 8, BV/TV, structure model index, Tb.N, and trabecular thickness significantly improved in the late ZOL group. The OVX and ZOL groups showed, respectively, higher and lower bone formation rates than the control group. Early ZOL treatment inhibited all bone microstructural changes seen after OVX. Late ZOL treatment significantly improved bone microstructure, although the structure did not recover to original levels. Early ZOL treatment resulted in a significantly better microstructure than late treatment. However, late treatment was still significantly better than no treatment.

[1]  Masako Ito,et al.  Assessment of bone quality using micro-computed tomography (micro-CT) and synchrotron micro-CT , 2009, Journal of Bone and Mineral Metabolism.

[2]  R. Rizzoli,et al.  Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats. , 2002, Bone.

[3]  D B Kimmel,et al.  Acute Changes in Trabecular Bone Connectivity and Osteoclast Activity in the Ovariectomized Rat In Vivo , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  H. Weinans,et al.  Bone loss dynamics result in trabecular alignment in aging and ovariectomized rats , 2006, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[5]  H. Väänänen,et al.  Clodronate Prevents Bone Loss in Aged Ovariectomized Rats , 1997, Calcified Tissue International.

[6]  S. Majumdar,et al.  The Temporal Changes of Trabecular Architecture in Ovariectomized Rats Assessed by MicroCT , 2001, Osteoporosis International.

[7]  H Weinans,et al.  Longitudinal micro-CT scans to evaluate bone architecture. , 2005, Journal of musculoskeletal & neuronal interactions.

[8]  R T Turner,et al.  The effects of ovariectomy and 17β‐estradiol on cortical bone histomorphometry in growing rats , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  A. Chines,et al.  Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. , 2004, Bone.

[10]  L. To,et al.  The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. , 2004, Bone.

[11]  J. Yang,et al.  Effects of oestrogen deficiency on rat mandibular and tibial microarchitecture. , 2003, Dento maxillo facial radiology.

[12]  H. Hogan,et al.  The Mechanical Properties of Cancellous Bone in the Proximal Tibia of Ovariectomized Rats , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  M. Glatt.  The bisphosphonate zoledronate prevents vertebral bone loss in mature estrogen-deficient rats as assessed by micro-computed tomography. , 2001, European cells & materials.

[14]  W. Jee,et al.  Prostaglandin E2 increased rat cortical bone mass when administered immediately following ovariectomy. , 1993, Bone and mineral.

[15]  Ralph Müller,et al.  Monitoring individual morphological changes over time in ovariectomized rats by in vivo micro-computed tomography. , 2006, Bone.

[16]  H. Oxlund,et al.  Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. , 2004, Bone.

[17]  H Weinans,et al.  Detecting and tracking local changes in the tibiae of individual rats: a novel method to analyse longitudinal in vivo micro-CT data. , 2004, Bone.

[18]  R. Lindsay,et al.  Temporal changes in cancellous bone structure of rats immediately after ovariectomy. , 1995, Bone.

[19]  Jacques P. Brown,et al.  Intravenous zoledronic acid in postmenopausal women with low bone mineral density. , 2002, The New England journal of medicine.

[20]  R. Recker,et al.  Trabecular bone microarchitecture after alendronate treatment of osteoporotic women , 2005, Current medical research and opinion.

[21]  Rik Huiskes,et al.  No effects of in vivo micro‐CT radiation on structural parameters and bone marrow cells in proximal tibia of wistar rats detected after eight weekly scans , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[22]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  Sundeep Khosla,et al.  Population‐Based Study of Age and Sex Differences in Bone Volumetric Density, Size, Geometry, and Structure at Different Skeletal Sites , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  Y. Ma,et al.  Intermittent treatments of prostaglandin E2 plus risedronate and prostaglandin E2 alone are equally anabolic on tibial shaft of ovariectomized rats. , 1995, Bone.

[25]  L. Dai,et al.  Differences of bone mass and bone structure in osteopenic rat models caused by spinal cord injury and ovariectomy , 2007, Osteoporosis International.

[26]  R. Huiskes,et al.  A three-dimensional digital image correlation technique for strain measurements in microstructures. , 2004, Journal of biomechanics.

[27]  G. Nicholson,et al.  Gene array identification of osteoclast genes: Differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor , 2004, Journal of cellular biochemistry.

[28]  G. Schmidmaier,et al.  Bisphosphonates incorporated in a poly(D,L-lactide) implant coating inhibit osteoclast like cells in vitro. , 2007, Journal of biomedical materials research. Part A.

[29]  J. Gasser.  The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them. , 2006, Current opinion in pharmacology.

[30]  T. Wronski,et al.  Long-term effects of ovariectomy and aging on the rat skeleton , 1989, Calcified Tissue International.

[31]  Y. Takeuchi,et al.  Comparison of two assays for fibroblast growth factor (FGF)-23 , 2005, Journal of Bone and Mineral Metabolism.

[32]  T. Wronski,et al.  Time course of vertebral osteopenia in ovariectomized rats. , 1989, Bone.

[33]  G. Evans,et al.  Long-Term Zoledronic Acid Treatment Increases Bone Structure and Mechanical Strength of Long Bones of Ovariectomized Adult Rats , 2003, Calcified Tissue International.

[34]  Katsunori Yoshida,et al.  Association between pentosidine and arteriosclerosis in patients receiving hemodialysis , 2004, Journal of Clinical and Experimental Nephrology.

[35]  H. Bergmeister,et al.  Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. , 2004, Arthritis and rheumatism.

[36]  M. McDonald,et al.  Zoledronic acid improves femoral head sphericity in a rat model of perthes disease , 2005, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[37]  P. Geusens,et al.  Effect of 1alpha-vitamin D3 and estrogen therapy on cortical bone mechanical properties in the ovariectomized rat model. , 1996, Endocrinology.

[38]  N. Binkley,et al.  Zoledronate Prevents the Development of Absolute Osteopenia Following Ovariectomy in Adult Rhesus Monkeys , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  R. Theriault.  Zoledronic acid (Zometa®) use in bone disease , 2003, Expert review of anticancer therapy.

[40]  L. Mosekilde,et al.  Cortical bone mass, composition, and mechanical properties in female rats in relation to age, long-term ovariectomy, and estrogen substitution , 2004, Calcified Tissue International.